Abstract
Introduction: Metabolite, lipid, and lipoprotein lipid profiling can provide novel insights into mechanisms underlying incident dementia and Alzheimer's disease. Methods: We studied eight prospective cohorts with 22,623 participants profiled by nuclear magnetic resonance or mass spectrometry metabolomics. Four cohorts were used for discovery with replication undertaken in the other four to avoid false positives. For metabolites that survived replication, combined association results are presented. Results: Over 246,698 person-years, 995 and 745 cases of incident dementia and Alzheimer's disease were detected, respectively. Three branched-chain amino acids (isoleucine, leucine, and valine), creatinine and two very low density lipoprotein (VLDL)-specific lipoprotein lipid subclasses were associated with lower dementia risk. One high density lipoprotein (HDL; the concentration of cholesterol esters relative to total lipids in large HDL) and one VLDL (total cholesterol to total lipids ratio in very large VLDL) lipoprotein lipid subclass was associated with increased dementia risk. Branched-chain amino acids were also associated with decreased Alzheimer's disease risk and the concentration of cholesterol esters relative to total lipids in large HDL with increased Alzheimer's disease risk. Discussion: Further studies can clarify whether these molecules play a causal role in dementia pathogenesis or are merely markers of early pathology.
Original language | English (US) |
---|---|
Pages (from-to) | 723-733 |
Number of pages | 11 |
Journal | Alzheimer's and Dementia |
Volume | 14 |
Issue number | 6 |
DOIs | |
State | Published - Jun 2018 |
Externally published | Yes |
Keywords
- Alzheimer's disease
- Amino acids
- Biomarkers
- Dementia
- Metabolomics
ASJC Scopus subject areas
- Clinical Neurology
- Geriatrics and Gerontology
- Psychiatry and Mental health
- Cellular and Molecular Neuroscience
- Health Policy
- Developmental Neuroscience
- Epidemiology
Fingerprint
Dive into the research topics of 'Association of branched-chain amino acids and other circulating metabolites with risk of incident dementia and Alzheimer's disease: A prospective study in eight cohorts'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Alzheimer's and Dementia, Vol. 14, No. 6, 06.2018, p. 723-733.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Association of branched-chain amino acids and other circulating metabolites with risk of incident dementia and Alzheimer's disease
T2 - A prospective study in eight cohorts
AU - Tynkkynen, Juho
AU - Chouraki, Vincent
AU - van der Lee, Sven J.
AU - Hernesniemi, Jussi
AU - Yang, Qiong
AU - Li, Shuo
AU - Beiser, Alexa
AU - Larson, Martin G.
AU - Sääksjärvi, Katri
AU - Shipley, Martin J.
AU - Singh-Manoux, Archana
AU - Gerszten, Robert E.
AU - Wang, Thomas J.
AU - Havulinna, Aki S.
AU - Würtz, Peter
AU - Fischer, Krista
AU - Demirkan, Ayse
AU - Ikram, M. Arfan
AU - Amin, Najaf
AU - Lehtimäki, Terho
AU - Kähönen, Mika
AU - Perola, Markus
AU - Metspalu, Andres
AU - Kangas, Antti J.
AU - Soininen, Pasi
AU - Ala-Korpela, Mika
AU - Vasan, Ramachandran S.
AU - Kivimäki, Mika
AU - van Duijn, Cornelia M.
AU - Seshadri, Sudha
AU - Salomaa, Veikko
N1 - Funding Information: The Framingham Heart Study: This work was supported by the dedication of the Framingham Heart Study participants. This work received grants from the National Institute on Aging (R01 AG054076, AG016495, AG049505, AG049607, and AG033193), the National Institute of Neurological Disorders and Stroke (NS017950), and the National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK-HL081572) and support from the National Heart, Lung, and Blood Institute's Framingham Heart Study (contracts no. N01-HC-25195 and HHSN268201500001I). Funding Information: The Erasmus Rucphen Family (ERF) has received funding from the Centre for Medical Systems Biology (CMSB) and Netherlands Consortium for Systems Biology (NCSB), both within the framework of the Netherlands Genomics Initiative (NGI)/Netherlands Organization for Scientific Research (NWO). ERF study is also a part of EUROSPAN (European Special Populations Research Network) (FP6 STRP grant number 018947 [LSHG-CT-2006-01947]); European Network of Genomic and Genetic Epidemiology (ENGAGE) from the European Community's Seventh Framework Programme (FP7/2007-2013)/grant agreement HEALTH-F4-2007-201413; “Quality of Life and Management of the Living Resources” of 5th Framework Programme (no. QLG2-CT-2002-01254); FP7 project EUROHEADPAIN (no. 602633), the Internationale Stichting Alzheimer Onderzoek (ISAO); the Hersenstichting Nederland (HSN); and the JPND under the project PERADES (grant number 733051021, Defining Genetic, Polygenic and Environmental Risk for Alzheimer's Disease using multiple powerful cohorts, focused Epigenetics, and Stem cell metabolomics). Metabolomics measurements of ERF have been funded by Biobanking and Biomolecular Resources Research Infrastructure (BBMRI)–NL (184.021.007) and. A.D. is supported by a Veni grant (2015) from ZonMw. The ERF follow-up study is funded by CardioVasculair Onderzoek Nederland (CVON 2012-03). The authors are grateful to all study participants and their relatives, general practitioners, and neurologists for their contributions and P. Veraart for her help in genealogy, J. Vergeer for the supervision of the laboratory work, both Sven J. van der Lee and A. van der Spek for collection of the follow-up data and P. Snijders M.D. for his help in data collection of both baseline and follow-up data. Funding Information: DILGOM 2007 baseline survey was funded by the Academy of Finland (grant nos. 136895 and 263836). Funding Information: P.W. is supported by the Academy of Finland (294834) and the Novo Nordisk Foundation. The serum NMR metabolomics platform has been supported by the Sigrid Juselius Foundation and the Strategic Research Funding from the University of Oulu. M.A.K. works in a unit that is supported by the University of Bristol and UK Medical Research Council (MC_UU_1201/1). Funding Information: EGCUT was supported by European Union H2020 grants 692145, Est.RC grant IUT20-60 (A.M.) and PUT1665P (K.F.) EU Project no. 2014-2020.4.01.15-0012 (Gentransmed) and from the Estonian Ministry of Social Affairs. Funding Information: The Rotterdam Study: The metabolomics profiling for the Rotterdam Study was performed within the framework of the BBMRI Metabolomics Consortium funded by BBMRI-NL, a research infrastructure financed by the Dutch government (NWO, grant nr 184.021.007 and 184033111). Funding was further provided by the Netherlands Organisation for Health Research and Development (ZonMW) as part of the Joint Programming for Neurological Disease (JPND) as part of the program PERADES (Defining Genetic, Polygenic and Environmental Risk for Alzheimer's Disease using multiple powerful cohorts, focused Epigenetics and Stem cell metabolomics - grant number 733051021). This study was also funded by the European Union Innovative Medicine Initiative (IMI) programme under grant agreement No. 115975 as part of the Alzheimer Disease Apolipoprotein Pathology for Treatment Elucidation and Development (ADAPTED, https://www.imi-adapted.eu ); the European Union's Horizon 2020 research and innovation programme as part of the Common mechanisms and pathways in Stroke and Alzheimer's disease (CoSTREAM) project ( www.costream.eu , grant agreement No. 667375); European Union's Horizon 2020 research and innovation programme Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE) under the grant agreement No 645740 as part of the Personalized pREvention of Chronic DIseases (PRECeDI) project, the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (project: ORACLE, grant agreement No. 678543); The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, the Netherlands Organization for Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the municipality of Rotterdam. The authors are grateful to the study participants, the staff from the Rotterdam Study, and the participating general practitioners and pharmacists. Generation and management of the Illumina exome chip v1.0 array data for the Rotterdam Study (RS-I) was executed by the Human Genotyping Facility of the Genetic Laboratory of the Department of Internal Medicine ( http://www.glimdna.org/ ), Erasmus MC, Rotterdam, the Netherlands. Generation and management of GWAS genotype data for the Rotterdam Study (RS-I, RS-II, RS-III) was executed by the Human Genotyping Facility of the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands. The GWAS data sets are supported by the Netherlands Organization of Scientific Research NWO Investments (175.010.2005.011, 911-03-012), the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), and the Netherlands Genomics Initiative (NGI)/Netherlands Organization for Scientific Research (NWO) Netherlands Consortium for Healthy Aging (NCHA), project 050-060-810. This study makes use of an extended data set of RS-II and RS-III samples based on Illumina Omni 2.5 and 5.0 GWAS genotype data. This data set was funded by the Genetic Laboratory of the Department of Internal Medicine, the Department of Forensic Molecular Biology, and the Department of Dermatology, Erasmus MC, Rotterdam, the Netherlands. The Whitehall II study: The UK Medical Research Council (K013351; G0902037), the British Heart Foundation, and the US National Institutes of Health (R01HL36310, R01AG013196) have supported collection of data in the Whitehall II study. Funding Information: Health 2000 is funded by the National Institute for Health and Welfare (THL), the Finnish Centre for Pensions (ETK), The Social Insurance Institution of Finland (KELA), The Local Government Pensions Institution (KEVA), and other organizations listed on the website of the survey ( www.thl.fi/fi/tutkimus-ja-asiantuntijatyo/vaestotutkimukset/terveys-2000-2011/yhteistyokumppanit ). Funding Information: FINRISK 1997 has been mainly funded by the budgetary funds of the National Institute for Health and Welfare. Important additional funding has been obtained from the Academy of Finland, Finnish Foundation for Cardiovascular Research, and other domestic foundations. The NMR metabolomics determinations were funded by a grant from the Academy of Finland (no. 139635 to V.S.). Publisher Copyright: © 2018 The Authors
PY - 2018/6
Y1 - 2018/6
N2 - Introduction: Metabolite, lipid, and lipoprotein lipid profiling can provide novel insights into mechanisms underlying incident dementia and Alzheimer's disease. Methods: We studied eight prospective cohorts with 22,623 participants profiled by nuclear magnetic resonance or mass spectrometry metabolomics. Four cohorts were used for discovery with replication undertaken in the other four to avoid false positives. For metabolites that survived replication, combined association results are presented. Results: Over 246,698 person-years, 995 and 745 cases of incident dementia and Alzheimer's disease were detected, respectively. Three branched-chain amino acids (isoleucine, leucine, and valine), creatinine and two very low density lipoprotein (VLDL)-specific lipoprotein lipid subclasses were associated with lower dementia risk. One high density lipoprotein (HDL; the concentration of cholesterol esters relative to total lipids in large HDL) and one VLDL (total cholesterol to total lipids ratio in very large VLDL) lipoprotein lipid subclass was associated with increased dementia risk. Branched-chain amino acids were also associated with decreased Alzheimer's disease risk and the concentration of cholesterol esters relative to total lipids in large HDL with increased Alzheimer's disease risk. Discussion: Further studies can clarify whether these molecules play a causal role in dementia pathogenesis or are merely markers of early pathology.
AB - Introduction: Metabolite, lipid, and lipoprotein lipid profiling can provide novel insights into mechanisms underlying incident dementia and Alzheimer's disease. Methods: We studied eight prospective cohorts with 22,623 participants profiled by nuclear magnetic resonance or mass spectrometry metabolomics. Four cohorts were used for discovery with replication undertaken in the other four to avoid false positives. For metabolites that survived replication, combined association results are presented. Results: Over 246,698 person-years, 995 and 745 cases of incident dementia and Alzheimer's disease were detected, respectively. Three branched-chain amino acids (isoleucine, leucine, and valine), creatinine and two very low density lipoprotein (VLDL)-specific lipoprotein lipid subclasses were associated with lower dementia risk. One high density lipoprotein (HDL; the concentration of cholesterol esters relative to total lipids in large HDL) and one VLDL (total cholesterol to total lipids ratio in very large VLDL) lipoprotein lipid subclass was associated with increased dementia risk. Branched-chain amino acids were also associated with decreased Alzheimer's disease risk and the concentration of cholesterol esters relative to total lipids in large HDL with increased Alzheimer's disease risk. Discussion: Further studies can clarify whether these molecules play a causal role in dementia pathogenesis or are merely markers of early pathology.
KW - Alzheimer's disease
KW - Amino acids
KW - Biomarkers
KW - Dementia
KW - Metabolomics
UR - http://www.scopus.com/inward/record.url?scp=85042905746&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042905746&partnerID=8YFLogxK
U2 - 10.1016/j.jalz.2018.01.003
DO - 10.1016/j.jalz.2018.01.003
M3 - Article
C2 - 29519576
AN - SCOPUS:85042905746
SN - 1552-5260
VL - 14
SP - 723
EP - 733
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 6
ER -